NEW RECOMMENDATION BY THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: All patients with suspected gastritis should be examined by Pepsinogen I, Pepsinogen II and Gastrin-17 biomarkers

Read the release

Biohit has settled the dispute concerning a breach of the patent license agreement and therefore specifies its financial guidance for 2021

Read more

Recent clinical validation study confirms the accuracy of the new-generation GastroPanel® test in diagnosis of atrophic gastritis and Helicobacter pylori infection.

A new clinical validation study from Oulu University Hospital was recently published in a widespread international cancer journal (1), confirming that new-generation GastroPanel® test is highly accurate in diagnosing atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients.  Read more …

Biohit Oyj Board of Directors decided on new option scheme

Biohit Oyj’s Board of Directors has, based on authorization of Biohit Oyj’s General Shareholders’’ Meeting on September 9, 2020, decided on new option scheme to Group’s key personnel. Read more …